Filter by: patients
What is Zyflamend?

Zyflamend is an herbal extract of ten herbs including: Holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese gold thread and Scutellaria inhibit cyclooxygenase-2 activity and thereby reduce inflammation. It is promoted as having anti-inflammatory and antiaging properties.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Inflammation 4 2 Efficacy_none Efficacy_cant_tell
Immune system weak 1 1 Efficacy_cant_tell
Lymphedema 1 1 Efficacy_none
Pain 1 0
Other 1 0
Undifferentiated Inflammatory Arthritis 1 0

See all 9 patients currently taking Zyflamend

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
4

Reported Dosages

  1 other daily 2 g daily 2 other daily 3 other daily 100 mg daily
  3 Number of Patients: 3 1 Number of Patients: 1 4 Number of Patients: 4 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Zyflamend (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 50%
Personal research 1   Personal research: 50%
Course of treatment ended 1   Course of treatment ended: 50%

See all 2 patients who’ve stopped taking Zyflamend

Currently Taking Zyflamend

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Zyflamend

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Zyflamend

Always
2 50%
Usually
2 50%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Zyflamend

Very
1 25%
Somewhat
0 0%
A little
2 50%
Not at all
1 25%

Cost

Paid out of pocket

Cost of Zyflamend

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 50%
< $25
1 50%

Report created on May 26, 2012.